- Big Bank Phobia: Not Too Big to Fail
- Expect Your Health Care in Retirement to Hit $200,000
- Why Car Prices Vary From City To City
- Biotech Stock Mailbag: Vical, Sangamo, Spectrum Pharma
- 5 Worst Home Renovation Projects
Article
Options Trade Into Ziopharm's Sarcoma Drug Study Results
Options expert Tony Pelz says options are the best way to trade Ziopharma's looming palifosamide data.
11:00AM 02/26/13
Article
Dynavax Options Trade for Heplisav FDA Approval Decision
Options expert Tony Pelz offers investors a way to use options to trade Dynavax's upcoming FDA decision.
08:30AM 02/12/13
Article
Alexza Pharma: Premium Selling Options Strategy
A new options trade for Alexza going into an FDA drug approval decision.
11:27AM 12/12/12
Article
Amicus: Bullish Options Trade Into Clinical Trial Catalysts
Contributor Tony Pelz offers an options trade for those who believe Amicus shares are going higher.
09:05AM 12/04/12
Article
Dynavax: Speculative Upside Options Trade
How to use options to play a possible run-up in Dynavax prior to the FDA's approval decision.
07:31AM 11/20/12
Article
Exelixis: New Drug Approval Options Trade
Options wizard Tony Pelz suggests another way to trade Exelixis's FDA drug approval decision.
08:00AM 11/06/12
Article
Eli Lilly: Bearish Options Trade
Tony Pelz offers a short-term options trade to take advantage of end-of-year selling in Eli Lilly.
10:01AM 11/01/12
Article
Ziopharm: Options Trade for Phase III Data
How to play the high-risk release of results from Ziopharm's phase III study.
08:30AM 10/22/12
Article
How to Hedge Profits in Sarepta Therapeutics
Options guru Tony Pelz offers options trades for those who want to protect their Sarepta profits.
09:00AM 10/15/12
Article
NPS Pharma: Bullish Options Trade Into the Gattex FDA Panel
Biotech options expert Tony Pelz recommends a bullish options trade for the Oct. 16 Gattex FDA panel.
08:00AM 10/08/12